Financial Position - As of September 30, 2025, Lunai Bioworks Inc. reported cash and cash equivalents of $624,808 and an accumulated deficit of $507,643,549 [142]. - The company has a working capital deficit of $18,922,114, raising substantial doubt about its ability to continue as a going concern for one year after the financial statements are issued [142]. - Total assets decreased to $6,960,663 as of September 30, 2025, from $8,230,840 as of June 30, 2025 [158]. - Total liabilities decreased to $20,001,437 as of September 30, 2025, from $29,580,681 as of June 30, 2025 [159]. - The company incurred net cash used in operating activities of $1,349,110 for the three months ended September 30, 2025, compared to $2,016,328 in 2024 [160]. - Cash provided by financing activities was $1,343,357 for the three months ended September 30, 2025, compared to $2,029,183 in 2024 [162]. - The company has never generated revenues and does not anticipate earning any until its therapies or products are approved for marketing and sale [148]. Operational Performance - Operating expenses for the three months ended September 30, 2025, were $3,308,360, a decrease of $50,030,194 or approximately 94% compared to $53,338,554 in 2024 [149]. - General and administrative expenses decreased by $2,890,735 or approximately 55%, from $5,301,251 in 2024 to $2,410,516 in 2025 [150]. - Research and development expenses dropped by $365,782 or approximately 94%, from $390,189 in 2024 to $24,407 in 2025 [151]. - The company reported a net income of $2,819,021 for the three months ended September 30, 2025, compared to a net loss of $44,212,036 in 2024, representing a decrease in net loss of $47,031,057 or approximately 106% [153]. - As of September 30, 2025, the company had $624,808 in cash, an increase of 574% compared to $92,700 as of June 30, 2025 [157]. Business Development - Renovaro Biosciences aims to develop advanced allogeneic cell and gene therapies for long-term cancer remission and serious infectious diseases, pending necessary funding [117]. - The allogeneic cell therapy platform has completed the pre-IND and IND-enabling phase, focusing on long-term remission of solid tumors, particularly pancreatic cancer [122]. - BioSymetrics integrates multimodal data sources to advance biomarker discovery and therapeutic development, collaborating with pharmaceutical companies and healthcare providers [127][128]. - BioSymetrics has developed a proprietary knowledge graph, the Phenograph, mapping 5,856 diseases and 16,676 human genes to enhance drug target identification [131]. - The company screened 1,400 compounds in a zebrafish model, identifying a hit compound that showed efficacy in a mouse seizure model, progressing as a potential therapeutic [133]. - BioSymetrics intends to expand its platform across biopharmaceutical and healthcare markets, focusing on compliance with healthcare data privacy regulations [137]. Corporate Changes - GediCube, B.V., acquired in February 2024, filed for bankruptcy and will no longer be reported on starting in Q2 2026 [116]. - The company has incurred substantial recurring losses and is dependent on additional financing to fund operations [142].
ENOCHIAN BIOSCIE(ENOB) - 2026 Q1 - Quarterly Report